{"id":531897,"date":"2021-02-25T18:30:02","date_gmt":"2021-02-25T18:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531897"},"modified":"2021-02-25T18:30:02","modified_gmt":"2021-02-25T18:30:02","slug":"irritable-bowel-syndrome-ibs-competitive-landscape-report-2020-emerging-therapies-and-key-pharma-players-involved","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/irritable-bowel-syndrome-ibs-competitive-landscape-report-2020-emerging-therapies-and-key-pharma-players-involved_531897.html","title":{"rendered":"Irritable Bowel Syndrome (IBS) Competitive Landscape Report 2020: Emerging Therapies and Key Pharma Players Involved"},"content":{"rendered":"
\"Irritable<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Irritable Bowel Syndrome (IBS) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Irritable Bowel Syndrome (IBS) market. A detailed picture of the Irritable Bowel Syndrome (IBS) pipeline landscape is provided, which includes the disease overview and Irritable Bowel Syndrome (IBS) treatment guidelines. <\/div>\n

“Irritable Bowel Syndrome (IBS) Pipeline Insight, 2020<\/strong><\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Irritable Bowel Syndrome (IBS) market. A detailed picture of the Irritable Bowel Syndrome (IBS) pipeline landscape is provided, which includes the disease overview and Irritable Bowel Syndrome (IBS) treatment guidelines.<\/p>\n

\"\"<\/p>\n

The assessment part of the report embraces in-depth Irritable Bowel Syndrome commercial assessment<\/strong><\/a> and clinical assessment of the Irritable Bowel Syndrome (IBS) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Irritable Bowel Syndrome (IBS) collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.<\/p>\n

Irritable Bowel Syndrome (IBS), also known as spastic colon, irritable colon, mucous colitis, and spastic colitis, is a long-term digestive system condition, which causes cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. The symptoms can vary in severity and duration from person to person. However, they last at least three months for at least three days per month. IBS can cause intestinal damage in some cases. The condition is separate from inflammatory bowel disease and isn’t related to other bowel conditions.<\/p>\n

Request for detailed sample pages: https:\/\/www.delveinsight.com\/sample-request\/irritable-bowel-syndrome-ibs-pipeline-insight<\/span><\/a><\/strong><\/p>\n

“The total diagnosed prevalence of IBS in 7MM was found to be 101.5 Million in 2017.”<\/strong><\/p>\n

Scope of the report<\/strong><\/p>\n